It has become commonly accepted that women do worse than men following a heart attack or other coronary event. Earlier studies have documented that young women are more likely to die from cardiac-related events compared to men in the twelve months after hospital discharge. A new study published in the Canadian Journal of Cardiology, drawing on contemporary data from 26 hospitals, reports that young patients with acute coronary syndrome have good one-year prognosis, with men and women doing equally well.
Increasing stomach fat—especially abdominal visceral fat—has been associated with newly- Framingham Heart Study identified and worsening heart disease risk factors, according to a study published in the Journal of the American College of Cardiology.
A study presented at the last late-breaking trial session of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington, DC, USA) indicates that the Amplatzer Amulet left atrial appendage occluder device (St Jude Medical), for prevention of stroke in patients with atrial fibrillation, is associated with high implant success rates and a low rate of adverse effects.
Data from the PLATINUM DIVERSITY trial, which was presented at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington DC, USA), indicates that the risk of death or myocardial infarction after percutaneous coronary intervention (PCI) is significantly higher among women and minorities than it is among white men. Furthermore, the risk of post-PCI myocardial infarction is significantly increased among minorities.
The SENTINEL trial, which was presented at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington , DC, USA) today, has not meet its primary efficacy endpoint that patients undergoing transcatheter aortic valve implantation (TAVI) with a cerebral protection device (Sentinel, Claret Medical) would have a significant reduction in new lesion volume compared with those undergoing TAVI without the device. However, the primary efficacy endpoint has been met in a multivariate model.
At a symposium at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington, DC, USA), physicians discussed their first experiences with a metallic bioresorbable scaffold (Magmaris, Biotronik). The BIOSOLVE-II trial had previously established the safety and clinical performance of Magmaris, which received the CE mark in June this year.
Results of the REVELUTION study, simultaneously presented at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington, DC, USA) and published in the Journal of the American College of Cardiology today, indicate that a novel drug-filled stent (Medtronic) has a similar rate of in-stent late lumen loss at nine months as a zotarolimus-eluting permanent polymer stent (Resolute, Medtronic). The study, which is the first-in-human data for the drug-filled stent, also showed positive clinical outcomes.
Today, Medtronic presented new positive data from two large registries aimed at evaluating 30-day clinical performance outcomes for its self-expanding, recapturable and repositionable CoreValve Evolut R transcatheter aortic valve implantation (TAVI) device in “real-world” severe aortic stenosis patient populations at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington, DC, USA).
The FDA has approved St Jude Medical’s Amplatzer patent foramen ovale (PFO) occluder device for the prevention of stroke. Announced on 28 October, this clearance precedes a first report investigation of the final long-term outcomes of the RESPECT trial (which evaluated the Amplatzer device) that is due to be presented on 1 November at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington, DC, USA).
BIO-RESORT, presented at TCT today during a late-breaking trial session, has found no significant differences at one year between Medtronic’s Resolute Integrity (a durable polymer drug-eluting stent) and Boston Scientific’s Synergy and Biotronik’s Orsiro (both biodegradable polymer drug-eluting stents).
ILUMEN III, the first late-breaking to be presented at the 2016 Transcatheter Cardiovascular Therapeutics meeting (29 October-2 November, Washington, DC, USA), has met its primary endpoint that OCT-guided PCI is non-inferior to IVUS-guided PCI or to angiography-guided PCI in terms of post procedural minimal stent area. It also found that OCT-guided PCI was superior to angiography-guided PCI regarding stent expansion and procedural success.
Tryton Medical and Cardinal Health have announced that they have established a long-term strategic agreement for US distribution of the Tryton side-branch stent, pending regulatory approval. Tryton submitted a pre-market approval (PMA) application to the FDA for the Tryton side-Branch Stent in November 2015. If approved, the Tryton side-branch stent would be the first stent specifically indicated for the treatment of bifurcation lesions in the USA.
Valtech Cardio will present a symposium on mitral and tricuspid valve repair at the 2016 Transcatheter Cardiovascular Therapeutics conference (TCT) meeting (29 October–2 November, Washington, DC, USA). Additionally, updated two-year follow-up results of the multicentre Cardioband Mitral study and Cardioband Trucuspid initial experience will be presented by Karl-Heinz Kuck (director of Cardiology, Allegemienes Krankenhaus St Georg, Hamburg, Germany).
According to a study by researchers from the University of Turku (Finland), a smartphone app could detect myocardial infarction. Requiring no extra equipment, the app uses a phone’s built-in motion sensors—especially the gyroscope. Therefore, the used technology is similar to an app for detecting atrial fibrillation that the research group has also developed (and announced in August). The myocardial infarction detection app should be available for test use in 2017.
Corindus Vascular Robotics has received 510(k) clearance from the FDA for its CorPath GRX, the second generation of its CorPath vascular robotic system. A press release states that CorPath GRX significantly builds upon the CorPath platform, adding a significant number of key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. The company expects to commence commercialisation of the new system in the first quarter of 2017.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos